BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 95% based on the discounted cash flow analysis.
| Market cap | $3.38 Billion |
|---|---|
| Enterprise Value | $3.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.43 |
| Beta | 0.37 |
| Outstanding Shares | 375,000,000 |
| P/E Ratio | -2.18 |
|---|---|
| PEG | -2.94 |
| Price to Sales | 0.31 |
| Price to Book Ratio | -2.15 |
| Enterprise Value to Revenue | 0.42 |
| Enterprise Value to EBIT | 1.56 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | -0.49 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 236.27% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.11%▼ 63.71% |
|---|---|
| Total Invested | $2.72M▼ 99.77% |
| Investors Holding | 16▼ 227.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...